Jun Ye
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jun Ye has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Jie Xu
The Affiliated Taizhou People's Hospital of Nanjing Medical University
2 shared publications Ting Guo
Central Laboratory, The Affiliated Taizhou People’s Hospital of Nanjing Medical University, Taizhou School of Clinical Medicine, Nanjing Medical University , Taizhou , Jiangsu, 225300 , P.R. China
2 shared publicationsChensen Xu
Medical Department, Yangzhou University School of Medicine
1 shared publicationChuanmeng Zhang
The Center for Translational Medicine, Taizhou People's Hospital, Affiliated 5 to Nantong University, Taizhou, 225300, Jiangsu Province, China
1 shared publication- Chuanmeng Zhang
Department of Central Laboratory, Taizhou People's Hospital, Taizhou, 225300 Jiangsu Province, China
1 shared publication Chunsheng Fu
Taizhou People’s Hospital, Nanjing Medical University
1 shared publication
Latest Publications
- Open Access
- 27 March 2026
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 16, 1778487
Taraxacum alleviates ulcerative colitis, accompanied by the modulation of gut microbiota and restoration of intestinal barrier integrity
Background: Previous studies have shown that Taraxacum (TM) possesses strong antioxidant, anti-inflammatory, and antibacterial activities, but the mechanism regarding how TM attenuates IBD requires further exploration. This study evaluated the therapeutic effects of TM (0.15, 0.75, and 1.5 g/kg) on ulcerative colitis induced by Dextran Sulfate Sodium (DSS) in mice. Results: After 14 days of treatment following colitis induction, the herbal extract alleviated body weight loss and pathological abnormalities in the mice. In comparison to the DSS group, the 1.5 g/kg The TM therapy group had markedly elevated levels of colonic T-SOD, T-AOC, and GSH-Px (P < 0.05), alongside a substantial decrease in MDA content (P < 0.05) and inflammatory cytokines (IL-2, IL-6, IFN-g, TNF-a) (P < 0.05). Furthermore, TM markedly elevated the concentrations of volatile fatty acids (acetate, propionate, isobutyrate, and butyrate) in the cecal contents (P < 0.05). The 0.75 and 1.5 g/kg TM groups also elevated the expression of Claudin-1, Occludin, and ZO-1 (P < 0.05), whereas the DSS group showed reduced expression of these mucosal barrier proteins. Concerning gut microbiota, at the Phylum level, the relative abundance of Firmicutes was markedly elevated in the 1.5 g/kg TM groups (P < 0.05), Bacteroidetes exhibited a considerable reduction (P < 0.05); TM alleviated colitis concurrent with the restoration of beneficial Muribaculaceae and reduction of harmful Desulfovibrio . Notably, Desulfovibrio was inhibited more effectively than in 5-ASA, a change associated with intestinal homeostasis. Conclusion: TM alleviated colitis is correlated with enhancing antioxidant capacity, reducing inflammation, restoringbarrier integrity, and modulating the gut microbiota.
- 27 March 2026
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 16, 1778487
Open AccessTaraxacum alleviates ulcerative colitis, accompanied by the modulation of gut microbiota and restoration of intestinal barrier integrity
Background: Previous studies have shown that Taraxacum (TM) possesses strong antioxidant, anti-inflammatory, and antibacterial activities, but the mechanism regarding how TM attenuates IBD requires further exploration. This study evaluated the therapeutic effects of TM (0.15, 0.75, and 1.5 g/kg) on ulcerative colitis induced by Dextran Sulfate Sodium (DSS) in mice. Results: After 14 days of treatment following colitis induction, the herbal extract alleviated body weight loss and pathological abnormalities in the mice. In comparison to the DSS group, the 1.5 g/kg The TM therapy group had markedly elevated levels of colonic T-SOD, T-AOC, and GSH-Px (P < 0.05), alongside a substantial decrease in MDA content (P < 0.05) and inflammatory cytokines (IL-2, IL-6, IFN-g, TNF-a) (P < 0.05). Furthermore, TM markedly elevated the concentrations of volatile fatty acids (acetate, propionate, isobutyrate, and butyrate) in the cecal contents (P < 0.05). The 0.75 and 1.5 g/kg TM groups also elevated the expression of Claudin-1, Occludin, and ZO-1 (P < 0.05), whereas the DSS group showed reduced expression of these mucosal barrier proteins. Concerning gut microbiota, at the Phylum level, the relative abundance of Firmicutes was markedly elevated in the 1.5 g/kg TM groups (P < 0.05), Bacteroidetes exhibited a considerable reduction (P < 0.05); TM alleviated colitis concurrent with the restoration of beneficial Muribaculaceae and reduction of harmful Desulfovibrio . Notably, Desulfovibrio was inhibited more effectively than in 5-ASA, a change associated with intestinal homeostasis. Conclusion: TM alleviated colitis is correlated with enhancing antioxidant capacity, reducing inflammation, restoringbarrier integrity, and modulating the gut microbiota.
- Open Access
- 1 January 2024
- Published by Walter de Gruyter GmbH in Open Life Sciences
- Vol. 19 (1) , 20220915
The expression and biological role of complement C1s in esophageal squamous cell carcinoma
The present work focused on investigating the role of the altered expression of complement C1s in proliferation and apoptosis of esophageal squamous cell carcinoma (ESCC) cells and explore its biological functions in ESCC, so as to lay a theoretical foundation and provide certain clinical reference for diagnosing and treating ESCC. Complement C1s expression within ESCC was assessed, and its clinical pathological characteristics in ESCC patients were analyzed. Subsequently, in vitro experiments were performed to further explore the mechanisms by which complement C1s affected ESCC. According to the results, complement C1s expression within ESCC markedly increased relative to adjacent non-cancerous samples. High C1s expression showed positive relation to race, residual lesion, and tumor location of ESCC patients. Complement C1s affected ESCC cell proliferation and apoptosis. Notably, C1s knockdown significantly inhibited ESCC cell proliferation and enhanced their apoptosis. C1s suppressed ESCC cell proliferation via Wnt1/β-catenin pathway and promoted their apoptosis through modulating the expression of Bcl2, Bax, and cleaved-caspase3.
- 1 January 2024
- Published by Walter de Gruyter GmbH in Open Life Sciences
- Vol. 19 (1) , 20220915
Open AccessThe expression and biological role of complement C1s in esophageal squamous cell carcinoma
The present work focused on investigating the role of the altered expression of complement C1s in proliferation and apoptosis of esophageal squamous cell carcinoma (ESCC) cells and explore its biological functions in ESCC, so as to lay a theoretical foundation and provide certain clinical reference for diagnosing and treating ESCC. Complement C1s expression within ESCC was assessed, and its clinical pathological characteristics in ESCC patients were analyzed. Subsequently, in vitro experiments were performed to further explore the mechanisms by which complement C1s affected ESCC. According to the results, complement C1s expression within ESCC markedly increased relative to adjacent non-cancerous samples. High C1s expression showed positive relation to race, residual lesion, and tumor location of ESCC patients. Complement C1s affected ESCC cell proliferation and apoptosis. Notably, C1s knockdown significantly inhibited ESCC cell proliferation and enhanced their apoptosis. C1s suppressed ESCC cell proliferation via Wnt1/β-catenin pathway and promoted their apoptosis through modulating the expression of Bcl2, Bax, and cleaved-caspase3.
- Open Access
- 12 June 2023
- Published by Springer Nature in Discover Oncology
- Vol. 14 (1) , 1-18
A demonstration based on multi-omics transcriptome sequencing data revealed disulfidptosis heterogeneity within the tumor microenvironment of esophageal squamous cell carcinoma
Background: It is of great concern to identify prognostic signatures for the prediction and prediction of esophageal squamous cell carcinoma (ESCC), which is the lethal pathological type of malignancy. Method: Bulk RNA sequencing and scRNA-seq data were retrieved from GSE53624, GSE53622, and GSE188900. Disulfidptosis-related differentially expressed genes (DEGs) were identified between disulfidptosis-high score and disulfidptosis-low score groups. Functional annotation of DEGs were analyzed by Gene Ontology (GO). Consistent clustering and co-expression modules were analyzed, and then constructed a risk score model via multivariate Cox regression analysis. Immune infiltration and immunotherapy response analyses were conducted based on risk score. qRT-PCR, colony formation assay, and flow cytometry analysis were conducted in KYSE-150 and TE-1 cell lines. Results: Seven genes (CD96, CXCL13, IL2RG, LY96, TPK1, ACAP1, and SOX17) were selected as marker genes. CD96 and SOX17 are independent prognostic signatures for ESCC patients, with a significant correlation with infiltrated immune cells. ESCC patients had worse response to nivolumab in the high-risk group. Through cellular experiments, we found that CD96 expression was associated with apoptosis and cell cycle ESCC cells. Conclusion: In a word, the risk score based on disulfidptosis is associated with prognosis and the immune microenvironment, which may direct immunotherapy of ESCC. The key gene of risk score, namely CD96, plays a role in proliferation and apoptosis in ESCC. We offer an insight into the exploration of the genomic etiology of ESCC for its clinical management.
- 12 June 2023
- Published by Springer Nature in Discover Oncology
- Vol. 14 (1) , 1-18
Open AccessA demonstration based on multi-omics transcriptome sequencing data revealed disulfidptosis heterogeneity within the tumor microenvironment of esophageal squamous cell carcinoma
Background: It is of great concern to identify prognostic signatures for the prediction and prediction of esophageal squamous cell carcinoma (ESCC), which is the lethal pathological type of malignancy. Method: Bulk RNA sequencing and scRNA-seq data were retrieved from GSE53624, GSE53622, and GSE188900. Disulfidptosis-related differentially expressed genes (DEGs) were identified between disulfidptosis-high score and disulfidptosis-low score groups. Functional annotation of DEGs were analyzed by Gene Ontology (GO). Consistent clustering and co-expression modules were analyzed, and then constructed a risk score model via multivariate Cox regression analysis. Immune infiltration and immunotherapy response analyses were conducted based on risk score. qRT-PCR, colony formation assay, and flow cytometry analysis were conducted in KYSE-150 and TE-1 cell lines. Results: Seven genes (CD96, CXCL13, IL2RG, LY96, TPK1, ACAP1, and SOX17) were selected as marker genes. CD96 and SOX17 are independent prognostic signatures for ESCC patients, with a significant correlation with infiltrated immune cells. ESCC patients had worse response to nivolumab in the high-risk group. Through cellular experiments, we found that CD96 expression was associated with apoptosis and cell cycle ESCC cells. Conclusion: In a word, the risk score based on disulfidptosis is associated with prognosis and the immune microenvironment, which may direct immunotherapy of ESCC. The key gene of risk score, namely CD96, plays a role in proliferation and apoptosis in ESCC. We offer an insight into the exploration of the genomic etiology of ESCC for its clinical management.
- Open Access
- 1 June 2023
- Published by Taylor & Francis in International Journal of General Medicine
- Vol. ume 16, 2405-2417
Expression and Clinical Significance of TIGIT in Primary Breast Cancer
Purpose: The roles of T cell immunoreceptor with Ig and ITIM domains (TIGIT) in the diagnosis of primary breast cancer (PBC) are still unclear. This study was designed to investigate the expression of TIGIT in PBC patients, with an aim to analyze its diagnostic value in PBC. Patients and Methods: We first explore the expression of TIGIT in cancer patients based on TCGA database, and then we analyzed its correlation with clinicopathological features. Afterwards, we compared the protein and mRNA expressions of TIGIT in two BC cell lines (MCF-7 and MDA-MB-231) and normal breast epithelial cell line (MCF-10A). Subsequently, 56 PBC female patients admitted to the Taizhou People’s Hospital from October 2018 to June 2021 were included in this study. Flow cytometry was used to detect TIGIT level on peripheral blood CD3+ T cells of PBC patients and healthy controls. TIGIT expression in PBC tissues was detected by immunohistochemistry (IHC) and immunofluorescence staining. Results: TCGA database showed that compared with adjacent tissues, TIGIT was significantly upregulated in tumor tissues. High TIGIT expression was positively correlated with tumor stage and negatively correlated with recurrence free survival (RFS) and overall survival (OS). TIGIT level in BC cell lines, peripheral blood and tumor tissues of PBC patients was significantly higher than that of control (P < 0.05). TIGIT level was correlated with age (P < 0.05), rather than tumor size, pathological type, lymph node metastasis, ER, PR, HER-2, and P53. ROC curve showed that the optimal critical value of peripheral blood TIGIT for BC screening was 23.38%. Postoperative TIGIT level in peripheral blood was significantly decreased compared to the preoperative TIGIT level (P < 0.05). Conclusion: TIGIT was upregulated in PBC and was correlated with age. It may be a potential target for the diagnosis and immunotherapy of PBC.
- 1 June 2023
- Published by Taylor & Francis in International Journal of General Medicine
- Vol. ume 16, 2405-2417
Open AccessExpression and Clinical Significance of TIGIT in Primary Breast Cancer
Purpose: The roles of T cell immunoreceptor with Ig and ITIM domains (TIGIT) in the diagnosis of primary breast cancer (PBC) are still unclear. This study was designed to investigate the expression of TIGIT in PBC patients, with an aim to analyze its diagnostic value in PBC. Patients and Methods: We first explore the expression of TIGIT in cancer patients based on TCGA database, and then we analyzed its correlation with clinicopathological features. Afterwards, we compared the protein and mRNA expressions of TIGIT in two BC cell lines (MCF-7 and MDA-MB-231) and normal breast epithelial cell line (MCF-10A). Subsequently, 56 PBC female patients admitted to the Taizhou People’s Hospital from October 2018 to June 2021 were included in this study. Flow cytometry was used to detect TIGIT level on peripheral blood CD3+ T cells of PBC patients and healthy controls. TIGIT expression in PBC tissues was detected by immunohistochemistry (IHC) and immunofluorescence staining. Results: TCGA database showed that compared with adjacent tissues, TIGIT was significantly upregulated in tumor tissues. High TIGIT expression was positively correlated with tumor stage and negatively correlated with recurrence free survival (RFS) and overall survival (OS). TIGIT level in BC cell lines, peripheral blood and tumor tissues of PBC patients was significantly higher than that of control (P < 0.05). TIGIT level was correlated with age (P < 0.05), rather than tumor size, pathological type, lymph node metastasis, ER, PR, HER-2, and P53. ROC curve showed that the optimal critical value of peripheral blood TIGIT for BC screening was 23.38%. Postoperative TIGIT level in peripheral blood was significantly decreased compared to the preoperative TIGIT level (P < 0.05). Conclusion: TIGIT was upregulated in PBC and was correlated with age. It may be a potential target for the diagnosis and immunotherapy of PBC.
- Open Access
- 7 December 2022
- Published by Elsevier in Pharmacological Research
- Vol. 187, 106593
RNA-binding motif 4 promotes angiogenesis in HCC by selectively activating VEGF-A expression
- 7 December 2022
- Published by Elsevier in Pharmacological Research
- Vol. 187, 106593
Open AccessRNA-binding motif 4 promotes angiogenesis in HCC by selectively activating VEGF-A expression
- 14 May 2020
- Published by Springer Nature in Molecular Diagnosis & Therapy
- Vol. 24 (5) , 523-536
Prognostic Value of L-Type Amino Acid Transporter 1 (LAT1) in Various Cancers: A Meta-Analysis
Background and Objective The L-type amino acid transporter 1 (LAT1, SLC7A5) is overexpressed in various types of cancer and has been thought to assist cancer progression through its uptake of neutral amino acids. However, the prognostic role of LAT1 in human cancers remains uncharacterized. Therefore, we conducted this meta-analysis to determine the prognostic significance of LAT1 in various cancers. Methods We systematically searched the PubMed, Web of Science, EMBASE, Chinese National Knowledge Infrastructure, and WanFang databases to collect relevant cohort studies investigating the prognostic value of LAT1 expression in patients with cancer. Hazard ratios (HRs) with corresponding 95% confidence intervals (CIs) were pooled to clarify the association between the LAT1 expression and the survival of patients with cancer. Odds ratios (ORs) with 95% CIs were calculated to appraise the correlation between LAT1 and the clinicopathological characteristics in patients with cancer. Results A total of 32 eligible articles, including 34 cohorts and 6410 patients, were enrolled in this meta-analysis. Our results demonstrated that high LAT1 expression was significantly associated with poor overall survival (HR = 1.66, 95% CI 1.41–1.96, P < 0.001), cancer-specific survival (HR = 1.64, 95% CI 1.31–2.05, P < 0.001), disease-free survival (HR = 1.55, 95% CI 1.31–1.83, P < 0.001), and progression-free survival (HR = 1.18, 95% CI 1.02–1.37, P = 0.026) in patients with cancer. In addition, we found that the elevated expression level of LAT1 was significantly related to certain phenotypes of tumor aggressiveness, such as tumor size, clinical stage, T stage, lymphatic invasion, vascular invasion, tumor differentiation, Ki-67, CD34, CD98, p53, and system ASC amino acid transporter-2. Conclusions Elevated expression of LAT1 is associated with poor prognosis in human cancers and may serve as a potential prognostic marker and therapeutic target for patients with malignancies.
- 14 May 2020
- Published by Springer Nature in Molecular Diagnosis & Therapy
- Vol. 24 (5) , 523-536
Prognostic Value of L-Type Amino Acid Transporter 1 (LAT1) in Various Cancers: A Meta-Analysis
Background and Objective The L-type amino acid transporter 1 (LAT1, SLC7A5) is overexpressed in various types of cancer and has been thought to assist cancer progression through its uptake of neutral amino acids. However, the prognostic role of LAT1 in human cancers remains uncharacterized. Therefore, we conducted this meta-analysis to determine the prognostic significance of LAT1 in various cancers. Methods We systematically searched the PubMed, Web of Science, EMBASE, Chinese National Knowledge Infrastructure, and WanFang databases to collect relevant cohort studies investigating the prognostic value of LAT1 expression in patients with cancer. Hazard ratios (HRs) with corresponding 95% confidence intervals (CIs) were pooled to clarify the association between the LAT1 expression and the survival of patients with cancer. Odds ratios (ORs) with 95% CIs were calculated to appraise the correlation between LAT1 and the clinicopathological characteristics in patients with cancer. Results A total of 32 eligible articles, including 34 cohorts and 6410 patients, were enrolled in this meta-analysis. Our results demonstrated that high LAT1 expression was significantly associated with poor overall survival (HR = 1.66, 95% CI 1.41–1.96, P < 0.001), cancer-specific survival (HR = 1.64, 95% CI 1.31–2.05, P < 0.001), disease-free survival (HR = 1.55, 95% CI 1.31–1.83, P < 0.001), and progression-free survival (HR = 1.18, 95% CI 1.02–1.37, P = 0.026) in patients with cancer. In addition, we found that the elevated expression level of LAT1 was significantly related to certain phenotypes of tumor aggressiveness, such as tumor size, clinical stage, T stage, lymphatic invasion, vascular invasion, tumor differentiation, Ki-67, CD34, CD98, p53, and system ASC amino acid transporter-2. Conclusions Elevated expression of LAT1 is associated with poor prognosis in human cancers and may serve as a potential prognostic marker and therapeutic target for patients with malignancies.
- Open Access
- 13 November 2019
- Published by Hindawi Limited in Disease Markers
- Vol. 2019, 1-12
Association between Aspartate Aminotransferase-to-Platelet Ratio Index and Hepatocellular Carcinoma Risk in Patients with Chronic Hepatitis: A Meta-Analysis of Cohort Study
Background and Aim. Aspartate aminotransferase-to-platelet ratio index (APRI) is widely used in the assessment of fibrosis and cirrhosis, especially in patients with chronic hepatitis. However, the prognostic value of APRI in patients with chronic hepatitis with regard to the prediction of hepatocellular carcinoma (HCC) occurrence remains controversial. The objective of this meta-analysis is to investigate the association between APRI and HCC risk on the basis of cohort studies. Methods. We systematically reviewed PubMed, EMBASE, Web of Science, and Chinese National Knowledge Infrastructure databases for relevant cohort studies up to May 1, 2019. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) for total and subgroup analyses were calculated with Stata 12.0 software for the assessment of the relationship between APRI and HCC risk. Results. A total of 13 studies, involving 8897 patients, were included in the meta-analysis, of which 11 explored the association between pretreatment APRI and HCC risk and four reported the relationship between posttreatment APRI and HCC risk. Pooled results showed that an elevated level of pretreatment APRI was associated with increased HCC risk (, 95% CI: 1.78–3.68). When stratified by hepatitis type, high pretreatment APRI predicted HCC development in patients with chronic hepatitis B (CHB) and C (CHC) but not in alcoholic liver cirrhosis (ALC). In the subgroup analyses of study region, cut-off value, sample size, and analysis method, the relationship between high pretreatment APRI and increased HCC risk was significant. Meanwhile, patients with a high level of posttreatment APRI suffered from high HCC risk (, 95% CI: 2.52–5.42). Conclusion: Results revealed a significant association between elevated APRI and HCC development in patients with chronic hepatitis, suggesting that APRI might serve as a valuable predictor for HCC risk in patients with chronic hepatitis.- 13 November 2019
- Published by Hindawi Limited in Disease Markers
- Vol. 2019, 1-12
Open AccessAssociation between Aspartate Aminotransferase-to-Platelet Ratio Index and Hepatocellular Carcinoma Risk in Patients with Chronic Hepatitis: A Meta-Analysis of Cohort Study
Background and Aim. Aspartate aminotransferase-to-platelet ratio index (APRI) is widely used in the assessment of fibrosis and cirrhosis, especially in patients with chronic hepatitis. However, the prognostic value of APRI in patients with chronic hepatitis with regard to the prediction of hepatocellular carcinoma (HCC) occurrence remains controversial. The objective of this meta-analysis is to investigate the association between APRI and HCC risk on the basis of cohort studies. Methods. We systematically reviewed PubMed, EMBASE, Web of Science, and Chinese National Knowledge Infrastructure databases for relevant cohort studies up to May 1, 2019. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) for total and subgroup analyses were calculated with Stata 12.0 software for the assessment of the relationship between APRI and HCC risk. Results. A total of 13 studies, involving 8897 patients, were included in the meta-analysis, of which 11 explored the association between pretreatment APRI and HCC risk and four reported the relationship between posttreatment APRI and HCC risk. Pooled results showed that an elevated level of pretreatment APRI was associated with increased HCC risk (, 95% CI: 1.78–3.68). When stratified by hepatitis type, high pretreatment APRI predicted HCC development in patients with chronic hepatitis B (CHB) and C (CHC) but not in alcoholic liver cirrhosis (ALC). In the subgroup analyses of study region, cut-off value, sample size, and analysis method, the relationship between high pretreatment APRI and increased HCC risk was significant. Meanwhile, patients with a high level of posttreatment APRI suffered from high HCC risk (, 95% CI: 2.52–5.42). Conclusion: Results revealed a significant association between elevated APRI and HCC development in patients with chronic hepatitis, suggesting that APRI might serve as a valuable predictor for HCC risk in patients with chronic hepatitis.